Examining Impact of Insurance Type on Genetic Testing in Pediatric Neurology

IF 3.2 3区医学 Q2 CLINICAL NEUROLOGY

Pediatric neurology Pub Date : 2024-10-09 DOI:10.1016/j.pediatrneurol.2024.09.029

Sydney Carnes BA , Laura D. Fonseca MS , Deborah Lee BS , Ankur Parekh BS , Anna Robertson BS , Gogi Kumar MD

{"title":"Examining Impact of Insurance Type on Genetic Testing in Pediatric Neurology","authors":"Sydney Carnes BA , Laura D. Fonseca MS , Deborah Lee BS , Ankur Parekh BS , Anna Robertson BS , Gogi Kumar MD","doi":"10.1016/j.pediatrneurol.2024.09.029","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Studies that examine the impact of insurance type on the ease of obtaining genetic testing are scarce. Therefore, we aim to analyze how different types of insurance influence the time taken to obtain genetic test results among pediatric neurology patients.</div></div><div><h3>Methods</h3><div>This was a retrospective cohort study from Dayton Children’s Hospital. Patients who had at least one neurological genetic result found in the electronic medical record from January 1, 2014, to March 1, 2023, were included in the study. Variables collected include demographics, health insurance data, and genetic testing results.</div></div><div><h3>Results</h3><div>A total of 141 patients were included. Most patients were male (51.8%), white (78.0%), and not Hispanic/Latino (96.5%). The mean age at the time of genetic testing was 7.9 years. Most patients had Medicaid as their primary insurance (60.3%) when compared with private insurance (39.7%). Two hundred fifteen genetic reports were examined (137 Medicaid charts and 78 private insurance charts). There was no statistically significant difference from mean time lapse between test order date and results date for Medicaid patients (27.3 days) versus private insurance (31.5 days, <em>P</em> = 0.40). Molecular genetics testing and epilepsy gene panel order were the most common tests ordered for both Medicaid (86.1%, 37.2%) and private insurance (88.5%, 39.7%, respectively).</div></div><div><h3>Conclusions</h3><div>The mean time between test order date and results date was comparable between private- and Medicaid-insured patients. Our results suggest that there is no significant difference for time to result between pediatric neurology patients who carry public versus private insurance for genetic testing.</div></div>","PeriodicalId":19956,"journal":{"name":"Pediatric neurology","volume":"161 ","pages":"Pages 223-226"},"PeriodicalIF":3.2000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric neurology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0887899424003540","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Studies that examine the impact of insurance type on the ease of obtaining genetic testing are scarce. Therefore, we aim to analyze how different types of insurance influence the time taken to obtain genetic test results among pediatric neurology patients.

Methods

This was a retrospective cohort study from Dayton Children’s Hospital. Patients who had at least one neurological genetic result found in the electronic medical record from January 1, 2014, to March 1, 2023, were included in the study. Variables collected include demographics, health insurance data, and genetic testing results.

Results

A total of 141 patients were included. Most patients were male (51.8%), white (78.0%), and not Hispanic/Latino (96.5%). The mean age at the time of genetic testing was 7.9 years. Most patients had Medicaid as their primary insurance (60.3%) when compared with private insurance (39.7%). Two hundred fifteen genetic reports were examined (137 Medicaid charts and 78 private insurance charts). There was no statistically significant difference from mean time lapse between test order date and results date for Medicaid patients (27.3 days) versus private insurance (31.5 days, P = 0.40). Molecular genetics testing and epilepsy gene panel order were the most common tests ordered for both Medicaid (86.1%, 37.2%) and private insurance (88.5%, 39.7%, respectively).

Conclusions

The mean time between test order date and results date was comparable between private- and Medicaid-insured patients. Our results suggest that there is no significant difference for time to result between pediatric neurology patients who carry public versus private insurance for genetic testing.

查看原文本刊更多论文

研究保险类型对小儿神经科基因检测的影响。

背景：很少有研究探讨保险类型对获得基因检测结果难易程度的影响。因此，我们旨在分析不同类型的保险如何影响儿科神经病学患者获得基因检测结果所需的时间：这是一项来自代顿儿童医院的回顾性队列研究。研究对象包括从 2014 年 1 月 1 日至 2023 年 3 月 1 日期间在电子病历中至少发现一项神经系统基因检测结果的患者。收集的变量包括人口统计学、医疗保险数据和基因检测结果：结果：共纳入 141 名患者。大多数患者为男性（51.8%）、白人（78.0%）和非西班牙/拉丁美洲裔（96.5%）。基因检测时的平均年龄为 7.9 岁。与私人保险（39.7%）相比，大多数患者的主要保险是医疗补助（60.3%）。共检查了 215 份基因报告（137 份医疗补助病历和 78 份私人保险病历）。医疗补助计划患者（27.3 天）与私人保险患者（31.5 天，P = 0.40）从检测订单日期到结果日期之间的平均时间间隔没有明显的统计学差异。医疗补助计划（86.1%、37.2%）和私人保险（分别为 88.5%、39.7%）患者最常订购的检测项目是分子遗传学检测和癫痫基因检测：结论：私人保险和医疗补助保险患者从下达检验订单到得到检验结果的平均时间相当。我们的研究结果表明，儿科神经病学患者在接受基因检测时，公共保险与私人保险在检测时间上没有明显差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric neurology 医学-临床神经学

CiteScore

4.80

自引率

2.60%

发文量

176

审稿时长

78 days

期刊介绍： Pediatric Neurology publishes timely peer-reviewed clinical and research articles covering all aspects of the developing nervous system. Pediatric Neurology features up-to-the-minute publication of the latest advances in the diagnosis, management, and treatment of pediatric neurologic disorders. The journal''s editor, E. Steve Roach, in conjunction with the team of Associate Editors, heads an internationally recognized editorial board, ensuring the most authoritative and extensive coverage of the field. Among the topics covered are: epilepsy, mitochondrial diseases, congenital malformations, chromosomopathies, peripheral neuropathies, perinatal and childhood stroke, cerebral palsy, as well as other diseases affecting the developing nervous system.